Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa
| dc.rights.license | open | en_US |
| dc.contributor.author | TCHOUNGA, Boris Kevin | |
| dc.contributor.author | CHARPENTIER, C. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | COFFIE, Patrick A., P. A. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DABIS, Francois | |
| dc.contributor.author | DESCAMPS, D. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | EHOLIE, Serge Paul | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | EKOUEVI, Didier Koumavi | |
| dc.date.accessioned | 2021-02-18T13:34:10Z | |
| dc.date.available | 2021-02-18T13:34:10Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 1932-6203 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26289 | |
| dc.description.abstractEn | Introduction The long-term prognosis of HIV-2-infected patients receiving antiretroviral therapy (ART) is still challenging, due to the intrinsic resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) and the suboptimal response to some protease inhibitors (PI). The objective was to describe the 5-years outcomes among HIV-2 patients harboring drug-resistant viruses. Methods A clinic-based cohort of HIV-2-patients experiencing virologic failure, with at least one drug resistance mutation was followed from January 2012 to August 2017 in Côte d’Ivoire. Follow-up data included death, lost to follow-up (LTFU), immuno-virological responses. The Kaplan-Meier curve was used to estimate survival rates. Results A total of 31 HIV-2 patients with virologic failure and with at least one drug resistance mutation were included. Two-third of them were men, 28(90.3%) were on PI-based ART-regimen at enrolment and the median age was 50 years (IQR = 46–54). The median baseline CD4 count and viral load were 456 cells/mm3 and 3.7 log10 c/mL respectively, and the participants have been followed-up in median 57 months (IQR = 24–60). During this period, 21 (67.7%) patients switched at least one antiretroviral drug, including two (6.5%) and three (9.7%) who switched to a PI-based and an integrase inhibitor-based regimen respectively. A total of 10(32.3%) patients died and 4(12.9%) were LTFU. The 36 and 60-months survival rates were 68.5% and 64.9%, respectively. Among the 17 patients remaining in care, six(35.3%) had an undetectable viral load (<50 c/mL) and for the 11 others, the viral load ranged from 2.8 to 5.6 log10 c/mL. Twelve patients were receiving lopinavir at the time of first genotype, five(42%) had a genotypic susceptibility score (GSS) ≤1 and 4(33%) a GSS >2. Conclusions The 36-months survival rate among ART-experienced HIV-2 patients with drug-resistant viruses is below 70%,lower than in HIV-1. There is urgent need to improve access to second-line ART for patients living with HIV-2 in West Africa | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject | IDLIC | |
| dc.title.en | Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa | |
| dc.title.alternative | PLoS One | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1371/journal.pone.0236642 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 32756581 | en_US |
| bordeaux.journal | PLoS ONE | en_US |
| bordeaux.page | e0236642 | en_US |
| bordeaux.volume | 15 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.issue | 8 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | IDLIC | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PLoS%20ONE&rft.date=2020&rft.volume=15&rft.issue=8&rft.spage=e0236642&rft.epage=e0236642&rft.eissn=1932-6203&rft.issn=1932-6203&rft.au=TCHOUNGA,%20Boris%20Kevin&CHARPENTIER,%20C.&COFFIE,%20Patrick%20A.,%20P.%20A.&DABIS,%20Francois&DESCAMPS,%20D.&rft.genre=article |
